These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9605749)

  • 1. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants.
    Albor A; Kaku S; Kulesz-Martin M
    Cancer Res; 1998 May; 58(10):2091-4. PubMed ID: 9605749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro.
    Søe K; Hartmann H; Schlott B; Stevnsner T; Grosse F
    Oncogene; 2002 Sep; 21(43):6614-23. PubMed ID: 12242659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 dependence of topoisomerase I recruitment in vivo.
    Mao Y; Okada S; Chang LS; Muller MT
    Cancer Res; 2000 Aug; 60(16):4538-43. PubMed ID: 10969804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of DNA topoisomerase I activity by p53.
    Gobert C; Bracco L; Rossi F; Olivier M; Tazi J; Lavelle F; Larsen AK; Riou JF
    Biochemistry; 1996 May; 35(18):5778-86. PubMed ID: 8639538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.
    Lin J; Teresky AK; Levine AJ
    Oncogene; 1995 Jun; 10(12):2387-90. PubMed ID: 7784087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
    Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
    Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Loging WT; Reisman D
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1.
    Huang SM; Schönthal AH; Stallcup MR
    Oncogene; 2001 Apr; 20(17):2134-43. PubMed ID: 11360197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I.
    Ayrault O; Karayan L; Riou JF; Larsen CJ; Séité P
    Oncogene; 2003 Apr; 22(13):1945-54. PubMed ID: 12673200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SFV topoisomerase: sequence specificity in a genetically mapped interval.
    Palaniyar N; Fisher C; Parks R; Evans DH
    Virology; 1996 Jul; 221(2):351-4. PubMed ID: 8661446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
    Jõers A; Kristjuhan A; Kadaja L; Maimets T
    Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.
    Cowell IG; Okorokov AL; Cutts SA; Padget K; Bell M; Milner J; Austin CA
    Exp Cell Res; 2000 Feb; 255(1):86-94. PubMed ID: 10666337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.